 |
MARINA DEL REY
Saturday, February 2, 2008
8:30 AM-12:45 PM
The Ritz-Carlton
Marina del Rey, California
|
| |
| COURSE DIRECTOR |
|
|
Judith E. Karp, MD
Director, Adult Leukemia Program
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland |
| |
| CHAIR |
|
|
Richard I. Fisher, MD
Vice-President for Clinical Services
University of Rochester Medical Center
Director, James P. Wilmot Cancer Center
Director, Hematology/Oncology Division
Samuel E. Durand Professor of Medicine
Rochester, New York |
|
|
NEW YORK CITY
Saturday, March 1, 2008
8:30 AM-12:45 PM
Le Parker Meridien
New York, New York
|
| |
| COURSE DIRECTOR |
|
|
Judith E. Karp, MD
Director, Adult Leukemia Program
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland |
| |
| CHAIR |
|
|
Steven T. Rosen, MD, FACP
Professor of Medicine
Feinberg School of Medicine
Director, Robert H. Lurie Comprehensive
Cancer Center of Northwestern University
Director of Cancer Programs
Northwestern Memorial Hospital
Chicago, Illinois |
|
|
|
| PROGRAM DESCRIPTION |
|
|
| The primary objective of this program is to provide oncologists, pharmacists, and oncology nurses with current and clinically relevant information on diagnosis, classification, and optimal multidisciplinary management of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia and to help clinicians improve the quality of care they provide their patients. Following a case-based format, the presentations are intended to illustrate best practices in the diagnosis and management of hematologic tumors. |
| |
| POLICY ON FACULTY AND PROVIDER DISCLOSURE |
|
|
| It is the policy of The Johns Hopkins University School of Medicine and AKH Inc., that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/ unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME and AKH Inc. have established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials. |
| |
| AMERICANS WITH DISABILITIES ACT |
|
|
| The Johns Hopkins University School of Medicine, AKH Inc., and Advanced Strategies in Medicine fully comply with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs. |
|
|
| LEARNING OBJECTIVES |
|
|
At the conclusion of this activity, participants should be better prepared to:
|
|
| • |
Review recent advances in molecular diagnostic strategies for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia |
| • |
Evaluate current treatment strategies for patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia |
| • |
Discuss results from recent studies on investigational treatment strategies for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia |
| • |
Apply the latest approaches and advances in supportive care for patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia |
|
| |
| TARGET AUDIENCE |
|
|
This program is intended for physicians, pharmacists, and nurses who treat patients with hematologic malignancies.
There are no prerequisites for this educational program. |
| |
|
|
|
|
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine, AKH Inc., and Advanced Strategies in Medicine. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
 AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
*AKH Inc. is a provider approved by the California Board of Registered Nursing, Provider Number CEP12070, for 4.8 contact hours.
Credit Designation
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AKH Inc. has approved this pharmacist educational activity for 4.0 contact hours UPN 077-999-08-001-L01-P. Initial Release Date: 2/2/2008.
AKH Inc. designates this nurse educational activity for 4.0 contact hours (0.40 CEUs).
The Johns Hopkins University School of Medicine and
AKH Inc. take responsibility for the content, quality, and scientific integrity of this CE activity.
Credit is awarded to participants who listen to each presentation, complete the activity evaluation, and self-report credit form. Partial credit is not available to nurse and pharmacist participants. Statements of credit will be mailed within 6-8 weeks of the program date. There is no fee to participate.
Supported by an educational grant from Cephalon Oncology, Cephalon Inc. |
|
Program Description